Yonal-Hindilerden Ipek, Hindilerden Fehmi, Mastanzade Metban, Tiryaki Tarik Onur, Tasan-Yenigun Sevim, Bilen Yusuf, Aksoz Selcuk, Cagatay Arif Atahan, Nalcaci Meliha
Division of Hematology, Department of Internal Medicine, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey.
Hematology Clinic, Istanbul Bakirkoy Dr. Sadi Konuk Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
Front Oncol. 2021 Mar 18;11:601709. doi: 10.3389/fonc.2021.601709. eCollection 2021.
First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes from this viral infection due to the immunosuppression brought about by the underlying cancer and the effects of therapy. We present a 55-year-old woman diagnosed with relapsed/refractory Hodgkin's lymphoma (HL) who had been heavily pretreated with multiagent chemotherapy, autologous hematopoietic stem cell transplantation (autoHCT), allogeneic hematopoietic stem cell transplantation (alloHCT) and was complicated with EBV associated posttransplant lymphoproliferative disease (PTLD) and chronic graft-versus-host-disease (GVHD). The patient was recently treated with brentuximab and donor lymphocyte infusion (DLI) for relapse after alloHCT. She suffered from severe COVID-19 pneumonia and eventually succumbed to acute respiratory distress syndrome (ARDS) and multiorgan failure. Of note, this is the first reported case of COVID-19 in a HL patient who was being treated with brentuximab for relapse after alloHCT.
2019年12月在中国首次发现的2019冠状病毒病（COVID-19）已迅速演变成一场全球大流行。由于潜在癌症导致的免疫抑制以及治疗的影响，血液系统恶性肿瘤的存在预计会增加这种病毒感染出现不良后果的风险。我们报告一名55岁女性，诊断为复发/难治性霍奇金淋巴瘤（HL），此前接受过多种化疗药物、自体造血干细胞移植（autoHCT）、异基因造血干细胞移植（alloHCT）的强烈预处理，并发EB病毒相关的移植后淋巴细胞增生性疾病（PTLD）和慢性移植物抗宿主病（GVHD）。该患者最近在alloHCT后复发，接受了brentuximab和供体淋巴细胞输注（DLI）治疗。她患上了严重的COVID-19肺炎，最终死于急性呼吸窘迫综合征（ARDS）和多器官功能衰竭。值得注意的是，这是首例报告的在alloHCT后复发接受brentuximab治疗的HL患者感染COVID-19的病例。
